Borderline atypical ductal hyperplasia/low-grade ductal carcinoma in situ on breast needle core biopsy should be managed conservatively

American Journal of Surgical Pathology

Volumn 37, Issue 6, 2013, Pages 913-923

  VandenBussche, Christopher J ^a   Khouri, Nagi ^a   Sbaity, Eman ^a   Tsangaris, Theodore N ^a   Vang, Russell ^a   Tatsas, Armanda ^a   Cimino Mathews, Ashley ^a   Argani, Pedram ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Atypical duct hyperplasia; Breast; Core biopsy; Ductal carcinoma in situ

Indexed keywords

ARTICLE; BREAST TUMOR; FEMALE; HUMAN; HYPERPLASIA; INTRADUCTAL CARCINOMA; LARGE CORE NEEDLE BIOPSY; PATHOLOGY;

BIOPSY, LARGE-CORE NEEDLE; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; HYPERPLASIA;

EID: 84880142464     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31828ba25c     Document Type: Article

References (24)

1. Ma XJ, Salunga R, Tuggle JT, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA. 2003;100:5974-5979.
2. Sanders ME, Schuyler PA, Dupont WD, et al. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer. 2005;103:2481-2484.
3. Page DL, Dupont WD, Rogers LW, et al. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer. 1985;55:2698-2708.
4. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312:146-151.
5. Marshall LM, Hunter DJ, Connolly JL, et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev. 1997;6:297-301.
6. Silverstein MJ, Lagios MD, Groshen S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med. 1999;340:1455-1461.
7. Silverstein MJ, Lagios MD. Should all patients undergoing breast conserving therapy for DCIS receive radiation therapy? No. One size does not fit all: an argument against the routine use of radiation therapy for all patients with ductal carcinoma in situ of the breast who elect breast conservation. J Surg Oncol. 2007;95:605-609.
8. Di Saverio S, Catena F, Santini D, et al. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up. Breast Cancer Res Treat. 2008; 109:405-416.
9. Buchholz TA, Haffty BG, Harris JR. Should all patients undergoing breast conserving therapy for DCIS receive radiation therapy? Yes. Radiation therapy, an important component of breast conserving treatment for patients with ductal carcinoma in situ of the breast. J Surg Oncol. 2007;95:610-613.
10. Wong JS, Kaelin CM, Troyan SL, et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol. 2006;24:1031-1036.
11. Fisher ER, Dignam J, Tan-Chiu E, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer. 1999;86: 429-438.
12. Johnson NB, Collins LC. Update on percutaneous needle biopsy of nonmalignant breast lesions. Adv Anat Pathol. 2009;16:183-195.
13. Jacobs TW, Connolly JL, Schnitt SJ. Nonmalignant lesions in breast core needle biopsies: to excise or not to excise? Am J Surg Pathol. 2002;26:1095-1110.
14. Corben AD, Edelweiss M, Brogi E. Challenges in the interpretation of breast core biopsies. Breast J. 2010;16(suppl 1):S5-S9.
15. Bilous M. Breast core needle biopsy: issues and controversies. Mod Pathol. 2010;23(suppl 2):S36-S45.
16. Ely KA, Carter BA, Jensen RA, et al. Core biopsy of the breast with atypical ductal hyperplasia: a probabilistic approach to reporting. Am J Surg Pathol. 2001;25:1017-1021.
17. Ellis IO, Humphreys S, Michell M, et al. Best Practice No 179. Guidelines for breast needle core biopsy handling and reporting in breast screening assessment. J Clin Pathol. 2004;57:897-902.
18. Lee AH, Denley HE, Pinder SE, et al. Excision biopsy findings of patients with breast needle core biopsies reported as suspicious of malignancy (B4) or lesion of uncertain malignant potential (B3). Histopathology. 2003;42:331-336.
19. Sanders ME, Simpson JF. Can we know what to do when DCIS is diagnosed? Oncology (Huntingt). 2011;25:852-856.
20. Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27:5319-5324.
21. Adkisson CD, Bagaria SP, Parker AS, et al. Which eligible breast conservation patients choose mastectomy in the setting of newly diagnosed breast cancer? Ann Surg Oncol. 2012;19:1129-1136.
22. McGuire KP, Santillan AA, Kaur P, et al. Are mastectomies on the rise? A 13-year trend analysis of the selection of mastectomy versus breast conservation therapy in 5865 patients. Ann Surg Oncol. 2009;16:2682-2690.
23. Cao D, Lin C, Woo SH, et al. Separate cavity margin sampling at the time of initial breast lumpectomy significantly reduces the need for reexcisions. Am J Surg Pathol. 2005;29:1625-1632.
24. Schnitt SJ, Vincent-Salomon A. Columnar cell lesions of the breast. Adv Anat Pathol. 2003;10:113-124.